Farmas USA

SPX posible pnorama para esta semana ...

Futuros planos salvo el DOW en -0.8% ... Sera por el -10% de BA ?

AMRN

Jooe, pues muchas gracias , importante para mi que tenia en plan hacer una comprar al abrir.. Ojala no me den sustos el viernes de brujas , ya vera 

Publicación..hala, te quito el pumpeo Mr_Simpson :-)

https://finance.yahoo.com/news/trevena-announces-publication-apollo-1-110000935.html

Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain

Study Summary and Key Findings:

• In APOLLO-1, a Phase 3 clinical study, 389 patients were administered either oliceridine (TRV130), morphine or placebo intravenously (IV) for 48 hours following bunionectomy.
   
• There were 3 dosing regimens for oliceridine (0.1mg, 0.35mg, and 0.5mg) and one for morphine (1mg), each self-administered by the patient as needed to control their pain.
   
• Findings showed that the onset of analgesia for oliceridine was rapid and the proportion of treatment responders in the two higher oliceridine dosing regimens was similar to patients receiving morphine. 
   
• The most commonly reported adverse effects (AEs) were nausea, vomiting, headache, and dizziness.  Fewer patients receiving oliceridine discontinued treatment due to an AE than patients receiving morphine.  
   
• Efficacy, safety, and tolerability data provide important context for evaluating the benefit/risk profile of IV oliceridine compared to morphine, and suggest that oliceridine may provide an important treatment option for the management of patients experiencing moderate-to-severe acute pain.

Trevena

AXGT   2.19 +0.71 (+47.973) Pre-Market: 

esta es la decis que vende humos pero... si da doblones, ahi estoy 

https://finance.yahoo.com/news/axovant-reports-positive-interim-results-103000503.html

• 25-point (42%) mean improvement in the UPDRS Part III (motor) OFF score, with individual patient improvements of 14-points and 36-points respectively
• Benefit seen across all UPDRS OFF subscales at 3 months
• Reductions in ON state dyskinesias seen on the Rush Dyskinesia Rating Scale and diary ON time with dyskinesia
• Generally well-tolerated with no serious adverse events at 3 months
• First patient in second cohort expected to be dosed in Q2 2019
• Axovant to present at the Cowen and Company 39th Annual Health Care Conference on March 11th at 12:00 PM (Eastern Time)

Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease

TGTX

Fuera a 6.60  +5% haber si las cogemos un poquito más baratas otra vez,,,

SGMO

Más cromos a 9.70  promedio 9.93

TGTX
He hecho exactamente lo mismo, jeje. Vendidas las del viernes para un 5%.